Skip to main content
. 2015 May 27;6(25):21468–21478. doi: 10.18632/oncotarget.4097

Figure 4. Proliferation of T98G cells expressing either HMW or 18K FGF2 subjected to RNAi against Kapβ2 (B and C) or GTPγS/GDPβs treatment (D) were measured by MTT assays.

Figure 4

A. Growth of T98G cells expressing HMW FGF2, 18K FGF2 or empty plasmid, as well as subjected to RNAi against Kapβ2 vs scramble RNAi. B. Growth of T98G cells expressing 18K FGF2 were subjected to RNAi against Kapβ2 vs scramble RNAi. C. Growth of T98G cells expressing HMW FGF2 were subjected to RNAi against Kapβ2 vs scramble RNAi. D. Growth of T98G cells expressing HMW FGF2 were treated with GTPγS or GDPβs as well as control treatment. Data are shown as mean ± SEM of three independent experiments; *P < 0.05 versus respective control.